Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

News Conference News ESC 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

September 08, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

News Conference News ESOC 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

May 29, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

September 06, 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

News Conference News ESC 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

September 06, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

News Conference News EuroPCR 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

May 18, 2023

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.